Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:ECYT
- CUSIP: 29269A10
- Web: www.endocyte.com
Capitalization:- Market Cap: $60.03 million
- Outstanding Shares: 42,575,000
Average Prices:- 50 Day Moving Avg: $1.36
- 200 Day Moving Avg: $1.88
- 52 Week Range: $1.17 - $3.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.74
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $70,000.00
- Price / Sales: 857.58
- Book Value: $2.72 per share
- Price / Book: 0.52
Profitability:- EBIDTA: ($40,600,000.00)
- Net Margins: -61,437.14%
- Return on Equity: -32.68%
- Return on Assets: -31.29%
Debt:- Current Ratio: 22.81%
- Quick Ratio: 22.81%
Misc:- Average Volume: 484,653 shs.
- Beta: 1.62
- Short Ratio: 2.55
Frequently Asked Questions for Endocyte (NASDAQ:ECYT)
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte, Inc. (NASDAQ:ECYT) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.03. The firm had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the prior year, the company posted ($0.25) EPS. View Endocyte's Earnings History.
Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?
3 brokerages have issued 1-year target prices for Endocyte's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Endocyte's share price to reach $4.50 in the next twelve months. View Analyst Ratings for Endocyte.
What are analysts saying about Endocyte stock?
Here are some recent quotes from research analysts about Endocyte stock:
- 1. According to Zacks Investment Research, "Endocyte reported wider than expected loss in second-quarter 2017. During the quarter, the company stopped enrollment in the phase Ib study evaluating EC1456 for lung cancer as well as stop enrollment of taxane-naive metastatic castration-resistant prostate cancer patients for EC1169. The company now plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform, and its pipeline candidate EC2629. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Moreover, shares of the company have underperformed the industry year to date." (8/14/2017)
- 2. Cowen and Company analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Summit Therapeutics PLC (SUMM), Intec Pharma (NTEC), Cidara Therapeutics (CDTX), MaxCyte (MXCT), Galmed Pharmaceuticals (GLMD), MEI Pharma (MEIP), Otonomy (OTIC), Gemphire Therapeutics (GEMP), Affimed N.V. (AFMD), Zafgen (ZFGN), Ophthotech Corporation (OPHT), ADMA Biologics (ADMA), Dicerna Pharmaceuticals (DRNA), ProNAi Therapeutics (SRRA), Lipocine (LPCN), Aeglea BioTherapeutics (AGLE), Pfenex (PFNX) and Applied Genetic Technologies Corporation (AGTC).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- John C. Aplin Ph.D., Independent Chairman of the Board
- Michael A. Sherman, President, Chief Executive Officer, Director
- Michael T. Andriole, Chief Financial Officer
- Philip S. Low Ph.D., Chief Science Officer, Director
- Michael A. Brinkley, Vice President - Quality
- Christopher P. Leamon Ph.D., Vice President - Research
- P. David Mozley M.D., Vice President - Imaging
- Katherine K. Parker, Vice President of Human Resources
- Beth A. Taylor, Corporate Controller
- Cooper Lesley Russell, Director
Who owns Endocyte stock?
Endocyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (8.34%), Vanguard Group Inc. (3.13%), Pinnacle Associates Ltd. (1.84%), Goldman Sachs Group Inc. (1.01%), California Public Employees Retirement System (0.61%) and JPMorgan Chase & Co. (0.57%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.
Who sold Endocyte stock? Who is selling Endocyte stock?
Endocyte's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Vanguard Group Inc., Parametric Portfolio Associates LLC, Ameriprise Financial Inc., Pinnacle Associates Ltd. and Royal Bank of Canada. View Insider Buying and Selling for Endocyte.
Who bought Endocyte stock? Who is buying Endocyte stock?
Endocyte's stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., LMR Partners LLP, Spark Investment Management LLC, FMR LLC and Dimensional Fund Advisors LP. Company insiders that have bought Endocyte stock in the last two years include Fred A Middleton and Philip S Low. View Insider Buying and Selling for Endocyte.
How do I buy Endocyte stock?
Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
One share of Endocyte stock can currently be purchased for approximately $1.41.
MarketBeat Community Rating for Endocyte (NASDAQ ECYT)MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Endocyte (NASDAQ:ECYT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $4.50 (219.15% upside) |
Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/5/2017 | Wedbush | Downgrade | Outperform -> Neutral | $8.00 -> $2.00 | High |  |
| 6/2/2017 | Cowen and Company | Downgrade | Outperform -> Market Perform | | Low | |
| 11/11/2016 | Credit Suisse Group | Reiterated Rating | Buy | $7.00 | N/A | |
| 11/4/2015 | Royal Bank of Canada | Lower Price Target | Outperform | $13.00 -> $10.00 | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Endocyte (NASDAQ:ECYT)Earnings History by Quarter for Endocyte (NASDAQ ECYT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | ($0.25) | ($0.28) | | $0.01 million | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.28) | ($0.27) | | $0.01 million | View | N/A | |
| 3/10/2017 | Q4 2016 | ($0.25) | ($0.26) | | $0.01 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.27) | ($0.21) | | $0.03 million | View | Listen | |
| 8/4/2016 | Q2 | ($0.26) | ($0.25) | | $0.01 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.25) | ($0.24) | | $0.01 million | View | Listen | |
| 3/2/2016 | Q4 | ($0.27) | ($0.23) | | $0.01 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.27) | ($0.24) | | $0.03 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.30) | ($0.25) | | $0.01 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.24) | ($0.26) | | $0.01 million | View | N/A | |
| 3/2/2015 | Q414 | ($0.24) | ($0.19) | $2.55 million | $12.00 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.21) | ($0.14) | $5.10 million | $3.90 million | View | N/A | |
| 7/29/2014 | Q214 | $0.11 | $0.52 | $26.62 million | $49.17 million | View | N/A | |
| 5/2/2014 | Q114 | ($0.15) | ($0.09) | $15.07 million | $17.30 million | View | N/A | |
| 2/24/2014 | Q413 | ($0.14) | ($0.08) | $15.90 million | $17.30 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($0.06) | ($0.11) | $14.24 million | $14.50 million | View | N/A | |
| 4/15/2013 | Q413 | | ($0.10) | $8.50 million | $13.60 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Endocyte (NASDAQ:ECYT)2017 EPS Consensus Estimate: ($1.07)
2018 EPS Consensus Estimate: ($0.82)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q2 2017 | 1 | ($0.33) | ($0.33) | ($0.33) |
| Q3 2017 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q1 2018 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q2 2018 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q3 2018 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q4 2018 | 1 | ($0.21) | ($0.21) | ($0.21) |
(Data provided by Zacks Investment Research)
Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Endocyte (NASDAQ:ECYT)Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 28.80%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/30/2016 | Christopher P. Leamon | VP | Sell | 23,244 | $2.55 | $59,272.20 | |
| 5/10/2016 | Philip S Low | Insider | Buy | 11,375 | $3.52 | $40,040.00 | |
| 1/19/2016 | Fred A. Middleton | Director | Buy | 10,000 | $2.79 | $27,900.00 | |
| 1/15/2016 | Fred A. Middleton | Director | Buy | 20,000 | $2.80 | $56,000.00 | |
| 4/9/2014 | Allen Ritter | VP | Sell | 1,000 | $21.16 | $21,160.00 | |
| 3/21/2014 | Allen Ritter | VP | Sell | 8,000 | $33.11 | $264,880.00 | |
| 2/14/2014 | Philip Low | Insider | Sell | 6,000 | $15.00 | $90,000.00 | |
| 12/2/2013 | P Ron Ellis | CEO | Sell | 3,000 | $12.00 | $36,000.00 | |
| 9/16/2013 | Allen Ritter | VP | Sell | 2,000 | $17.06 | $34,120.00 | |
| 9/12/2013 | David Meek | Insider | Sell | 10,000 | $15.50 | $155,000.00 | |
| 9/3/2013 | P Ron Ellis | CEO | Sell | 3,000 | $14.54 | $43,620.00 | |
| 8/30/2013 | Allen Ritter | VP | Sell | 6,000 | $14.36 | $86,160.00 | |
| 8/6/2013 | Chandra Lovejoy | VP | Sell | 7,000 | $17.29 | $121,030.00 | |
| 8/1/2013 | P Ron Ellis | CEO | Sell | 3,000 | $18.12 | $54,360.00 | |
| 7/15/2013 | P Ron Ellis | CEO | Sell | 3,000 | $17.01 | $51,030.00 | |
| 5/28/2013 | Ann Hanham | Director | Sell | 9,900 | $14.10 | $139,590.00 | |
| 5/22/2013 | Ann Hanham | Director | Sell | 40,000 | $14.38 | $575,200.00 | |
| 5/17/2013 | Ann Hanham | Director | Sell | 37,200 | $14.41 | $536,052.00 | |
| 5/17/2013 | Binh Nguyen | VP | Sell | 17,300 | $14.42 | $249,466.00 | |
| 5/15/2013 | Ann Hanham | Director | Sell | 40,200 | $14.69 | $590,538.00 | |
| 5/14/2013 | Christopher P Leamon | VP | Sell | 5,000 | $14.70 | $73,500.00 | |
| 2/25/2013 | Chandra D Lovejoy | VP | Sell | 2,102 | $9.70 | $20,389.40 | |
| 12/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $9.05 | $19,991.45 | |
| 11/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $8.72 | $19,262.48 | |
(Data available from 1/1/2013 forward)
Headline Trends for Endocyte (NASDAQ:ECYT)
Latest Headlines for Endocyte (NASDAQ:ECYT)
| Source: |
|
| Date | Headline |
|---|
 | Endocyte to Present at the 2017 Cantor Global Healthcare Conference
feeds.benzinga.com - September 19 at 4:17 PM |
 | Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 17 at 4:44 PM |
 | Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 6:06 PM |
 | Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
finance.yahoo.com - September 6 at 6:06 PM |
 | Endocyte (ECYT) Announces Presentation at ESMO
www.streetinsider.com - September 6 at 5:45 AM |
| Endocyte (ECYT) Announces Presentation at ESMO - StreetInsider.com
www.streetinsider.com - September 6 at 12:44 AM |
| Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
finance.yahoo.com - September 5 at 7:42 PM |
| ETFs with exposure to Endocyte, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 11:03 PM |
| Analysts Anticipate Endocyte, Inc. (ECYT) to Announce -$0.21 EPS
www.americanbankingnews.com - August 30 at 4:06 AM |
| Endocyte, Inc. :ECYT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 7:05 PM |
| Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
feeds.benzinga.com - August 16 at 8:49 AM |
| Endocyte, Inc. (ECYT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 14 at 3:14 PM |
| Endocyte, Inc. (ECYT) Forecasted to Post Q3 2017 Earnings of ($0.23) Per Share
www.americanbankingnews.com - August 14 at 3:18 AM |
 | Biotech Stocks on Investors' Radar -- Dermira, Endocyte, FibroGen, and Global Blood Therapeutics
www.bizjournals.com - August 11 at 11:38 PM |
| Analysts Expect Endocyte, Inc. (NASDAQ:ECYT) to Announce -$0.22 EPS
www.americanbankingnews.com - August 11 at 6:30 PM |
| Endocyte, Inc. (ECYT) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:16 PM |
 | Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss - Nasdaq
www.nasdaq.com - August 9 at 6:15 PM |
| Edited Transcript of ECYT earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 6:15 PM |
| Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
finance.yahoo.com - August 9 at 6:15 PM |
| Endocyte reports 2Q loss
finance.yahoo.com - August 9 at 6:15 PM |
| Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:52 PM |
| Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
finance.yahoo.com - August 8 at 5:52 PM |
 | Endocyte misses by $0.03
seekingalpha.com - August 8 at 4:51 PM |
| Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
finance.yahoo.com - August 4 at 6:25 PM |
| Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat
finance.yahoo.com - August 4 at 6:25 PM |
| Endocyte Announces Second Quarter 2017 Earnings Conference Call - GlobeNewswire (press release)
globenewswire.com - August 2 at 4:47 AM |
| Endocyte Announces Second Quarter 2017 Earnings Conference ... - GlobeNewswire (press release)
www.globenewswire.com - August 1 at 11:46 PM |
| Endocyte Announces Second Quarter 2017 Earnings Conference Call
finance.yahoo.com - August 1 at 6:45 PM |
| What's in Store for Endocyte (ECYT) this Earnings Season?
www.nasdaq.com - July 26 at 6:43 PM |
| What's in Store for Endocyte (ECYT) this Earnings Season?
finance.yahoo.com - July 26 at 6:43 PM |
| -$0.25 Earnings Per Share Expected for Endocyte, Inc. (ECYT) This Quarter
www.americanbankingnews.com - July 24 at 12:36 PM |
| Endocyte, Inc. (NASDAQ:ECYT) Short Interest Update
www.americanbankingnews.com - July 17 at 7:18 AM |
| Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
finance.yahoo.com - July 13 at 7:24 PM |
| Analysts Anticipate Endocyte, Inc. (ECYT) to Post -$0.25 EPS
www.americanbankingnews.com - June 28 at 8:28 AM |
| ETFs with exposure to Endocyte, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 5:34 PM |
| Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 5:54 PM |
| Endocyte, Inc. (ECYT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - June 8 at 10:58 AM |
| Wedbush Comments on Endocyte, Inc.'s Q3 2017 Earnings (ECYT)
www.americanbankingnews.com - June 7 at 8:28 AM |
| ETFs with exposure to Endocyte, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 4:58 PM |
 | AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce
www.rttnews.com - June 5 at 11:40 AM |
| Endocyte, Inc. (ECYT) Cut to "Neutral" at Wedbush
www.americanbankingnews.com - June 5 at 9:15 AM |
| Endocyte Announces Clinical Updates for EC1456 and EC1169 - GlobeNewswire (press release)
globenewswire.com - June 4 at 4:58 PM |
| ValuEngine Downgrades Endocyte, Inc. (ECYT) to Strong Sell
www.americanbankingnews.com - June 3 at 4:28 PM |
| Endocyte, Inc. (ECYT) Stock Rating Lowered by Cowen and Company
www.americanbankingnews.com - June 2 at 5:42 PM |
| Endocyte Announces Clinical Updates for EC1456 and EC1169
finance.yahoo.com - June 2 at 4:21 PM |
| Endocyte stock plummets 30% on news of major workforce reduction; clinical trial changes
finance.yahoo.com - June 2 at 4:21 PM |
| Endocyte, Inc. :ECYT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:21 PM |
| Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - June 2 at 7:34 AM |
| Today's Research Reports on Stocks to Watch: Endocyte and CytRx
finance.yahoo.com - May 31 at 9:45 AM |
| Blog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting
finance.yahoo.com - May 31 at 9:45 AM |
Endocyte (ECYT) Chart for Wednesday, September, 20, 2017
